Regeneron backs two new trials: cemiplimab in transplant patients, blood cancer genetics study

Two new trial registrations naming Regeneron Pharmaceuticals as collaborator were both first posted on 2026-07-20.

• "CONTRAC-2" (NCT07715734), sponsored by Washington University School of Medicine, is a phase II, multicenter, open label, single arm, non-randomized trial using Simon's optimal two-stage design to evaluate the efficacy of cemiplimab in kidney transplant recipients with advanced cutaneous squamous cell carcinoma.¹ The trial is not yet recruiting, plans to enroll 22 participants, and its primary outcome is overall response rate, defined as the proportion of patients with Complete Response (CR) or Partial Response (PR), measured from start of cemiplimab treatment through completion of follow-up.¹
• The Rutgers University Study of the Genetics of Blood Cancers (NCT07714044), sponsored by Rutgers, The State University of New Jersey, is recruiting. The study aims to enroll at least 10,000 participants nationally including affecteds and unaffecteds via online study portal, collect surveys online and a saliva sample through the mail, sequence DNA, and conduct genetic analyses to identify novel variants and further study known variants associated with leukemia, lymphoma, myeloma and other blood cancers.² Its primary outcome looks at genetic risk variants associated with blood cancer, with genetic factors measured through whole exome sequencing and genome-wide genotyping array, then correlated with blood cancer subtype.²